IP Verse

Pharmaceutical Composition Containing An Anti-Nucleating Agent

PatentPatent Analysis

EP3165220

MERCK SHARP & DOHME
Application Number
EP16198994A
Filing Date
Dec 2, 2005
Status
Patent Maintained As Amended
Oct 11, 2024
Grant Date
Nov 13, 2024
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3283882B2
EP3678654B1
EP1841493B2

Biblio Summary

The patent EP3165220B2 was granted to Merck Sharp & Dohme on Nov 13, 2024 following the initial filing on Dec 2, 2005 under the application number EP16198994A . The current legal status of the patent is Patent Maintained As Amended.

AI Generated Summary New

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

TER MEER STEINMEISTER & PARTNER PATENTANWALTE MBBJan 3, 2020ADMISSIBLE
KRAUS & LEDERER PARTGMBBDec 17, 2019ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents